BiotechTube

Cetuximab + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuralgia

Conditions

Neuralgia, Complex Regional Pain Syndromes

Trial Timeline

Oct 1, 2015 → Oct 1, 2016

NCT ID
NCT02490436

About Cetuximab + Placebo

Cetuximab + Placebo is a phase 2 stage product being developed by Merck for Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02490436. Target conditions include Neuralgia, Complex Regional Pain Syndromes.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02490436Phase 2Completed

Competing Products

20 competing products in Neuralgia

See all competitors
ProductCompanyStageHype Score
Placebo + DS-5565Daiichi SankyoPre-clinical
23
QUTENZAAstellas PharmaApproved
85
ASP8477 + PlaceboAstellas PharmaPhase 2
52
E2007 (perampanel) + PlaceboEisaiPhase 2
52
E2007EisaiPhase 2/3
65
KHK6188 + PlaceboKyowa KirinPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
GalcanezumabEli LillyApproved
85
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
77
ABT-894 + ABT-894 + ABT-894 + placebo + DuloxetineAbbViePhase 2
52
MK-8291 + PlaceboMerckPhase 1
33
Etoricoxib + PlaceboMerckApproved
85
ADL5747 + Placebo + PregabalinMerckPhase 2
52
MK0759MerckPhase 2
52
MK0686MerckPhase 2
52
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
33
EMA401 + PlaceboNovartisPhase 2
52
pregabalinPfizerApproved
84
Lyrica (pregabalin) + PlaceboPfizerApproved
84
2-weeks placebo then gabapentin + 1-week placebo then gabapentinPfizerPre-clinical
22

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85